Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2HDB8
|
|||
| Drug Name |
Mosunetuzumab
|
|||
| Synonyms |
RG7828; RO7030816; BTCT4465A
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Approved | [1] | |
| Company |
Roche/Genentech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | Inhibitor | [2] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761263. | |||
| REF 2 | Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.